Press Releases

28-09-2023

Eckert & Ziegler Receives Award for Professional Training

25-09-2023, 23:17 CEST (Ad hoc press release)

Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma

13-09-2023

Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients

10-08-2023

Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023

21-07-2023, 15:21 CEST (Ad hoc press release)

Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.

08-06-2023

Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma

07-06-2023

ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.

30-05-2023

Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA

15-05-2023

​​​​​​​Reorganization in the Executive Board of Eckert & Ziegler

11-05-2023

Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023

08-05-2023

Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

25-04-2023, 17:59 CEST (Ad hoc press release)

Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance

20-04-2023

Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

12-04-2023

Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site

04-04-2023

Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

30-03-2023

​​​​​Eckert & Ziegler: Successful fiscal year 2022

24-03-2023

​​​​​​​Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)

23-03-2023

Eckert & Ziegler with Unchanged Dividend Proposal

03-03-2023

Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.

01-02-2023

Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting

17-01-2023, 12:47 CET (Ad hoc press release)

Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures